531 related articles for article (PubMed ID: 11234899)
1. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
[TBL] [Abstract][Full Text] [Related]
3. Eradication of human medulloblastoma tumor xenografts with a combination of O6-benzyl-2'-deoxyguanosine and 1,3-bis(2-chloroethyl)1-nitrosourea.
Kokkinakis DM; Moschel RC; Pegg AE; Schold SC
Clin Cancer Res; 1999 Nov; 5(11):3676-81. PubMed ID: 10589786
[TBL] [Abstract][Full Text] [Related]
4. Treatment of human brain tumor xenografts with O6-benzyl-2'-deoxyguanosine and BCNU.
Schold SC; Kokkinakis DM; Rudy JL; Moschel RC; Pegg AE
Cancer Res; 1996 May; 56(9):2076-81. PubMed ID: 8616853
[TBL] [Abstract][Full Text] [Related]
5. O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.
Wedge SR; Newlands ES
Br J Cancer; 1996 May; 73(9):1049-52. PubMed ID: 8624262
[TBL] [Abstract][Full Text] [Related]
6. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.
Koç ON; Reese JS; Davis BM; Liu L; Majczenko KJ; Gerson SL
Hum Gene Ther; 1999 Apr; 10(6):1021-30. PubMed ID: 10223735
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of BCNU antitumor efficacy by 9-substituted O6-benzylguanines. Effect of metabolism.
Kokkinakis DM; Moschel RC; Pegg AE; Schold SC
Cancer Chemother Pharmacol; 2000; 45(1):69-77. PubMed ID: 10647505
[TBL] [Abstract][Full Text] [Related]
8. Extended depletion of O6-methylguanine-DNA methyltransferase activity following O6-benzyl-2'-deoxyguanosine or O6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity.
Marathi UK; Dolan ME; Erickson LC
Cancer Res; 1994 Aug; 54(16):4371-5. PubMed ID: 8044784
[TBL] [Abstract][Full Text] [Related]
9. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases.
Cai Y; Wu MH; Xu-Welliver M; Pegg AE; Ludeman SM; Dolan ME
Cancer Res; 2000 Oct; 60(19):5464-9. PubMed ID: 11034089
[TBL] [Abstract][Full Text] [Related]
10. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J
Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789
[TBL] [Abstract][Full Text] [Related]
11. O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.
Phillips WP; Willson JK; Markowitz SD; Zborowska E; Zaidi NH; Liu L; Gordon NH; Gerson SL
Cancer Res; 1997 Nov; 57(21):4817-23. PubMed ID: 9354444
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide.
Reese JS; Davis BM; Liu L; Gerson SL
Clin Cancer Res; 1999 Jan; 5(1):163-9. PubMed ID: 9918215
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
Liu L; Schwartz S; Davis BM; Gerson SL
Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916
[TBL] [Abstract][Full Text] [Related]
14. Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine.
Loktionova NA; Xu-Welliver M; Crone TM; Kanugula S; Pegg AE
Biochem Pharmacol; 1999 Jul; 58(2):237-44. PubMed ID: 10423163
[TBL] [Abstract][Full Text] [Related]
15. Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations.
Bacolod MD; Johnson SP; Pegg AE; Dolan ME; Moschel RC; Bullock NS; Fang Q; Colvin OM; Modrich P; Bigner DD; Friedman HS
Mol Cancer Ther; 2004 Sep; 3(9):1127-35. PubMed ID: 15367707
[TBL] [Abstract][Full Text] [Related]
16. Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice.
Kokkinakis DM; Hoffman RM; Frenkel EP; Wick JB; Han Q; Xu M; Tan Y; Schold SC
Cancer Res; 2001 May; 61(10):4017-23. PubMed ID: 11358820
[TBL] [Abstract][Full Text] [Related]
17. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair.
Spiro TP; Gerson SL; Liu L; Majka S; Haaga J; Hoppel CL; Ingalls ST; Pluda JM; Willson JK
Cancer Res; 1999 May; 59(10):2402-10. PubMed ID: 10344750
[TBL] [Abstract][Full Text] [Related]
18. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.
Liu L; Markowitz S; Gerson SL
Cancer Res; 1996 Dec; 56(23):5375-9. PubMed ID: 8968088
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.
Friedman HS; Dolan ME; Moschel RC; Pegg AE; Felker GM; Rich J; Bigner DD; Schold SC
J Natl Cancer Inst; 1992 Dec; 84(24):1926-31. PubMed ID: 1334154
[TBL] [Abstract][Full Text] [Related]
20. O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials.
Keir ST; Dolan ME; Pegg AE; Lawless A; Moschel RC; Bigner DD; Friedman HS
Cancer Chemother Pharmacol; 2000; 45(6):437-40. PubMed ID: 10854129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
